The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results ...

DMU will be part of a consortium laying the foundation for future medicines that are affordable, safe, effective, and ...

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...

Pharmaceutical company Takeda is pioneering a technology-enabled, patient-centered future for plasma-derived therapies ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

The finest minds from the pharma firmament will also be sharing insights on the changing landscape and on the new imperatives ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus. NEW ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

We have already seen the first wave of AI-powered dangers. Deepfakes, bot accounts, and algorithmic manipulation on social ...